NEW YORK--Sept. 24, 2007--Delcath Systems, Inc. (Nasdaq:DCTH) today announced that its Chief Executive Officer, Richard L. Taney, will make a presentation titled, "Isolated High Dose Drug Delivery for the Treatment of Cancer and Hepatitis," at the 12th Annual Drug Delivery Technologies and Deal Making Conference. The Delcath presentation is scheduled for 11:00 AM Eastern Time on Tuesday, September 25, 2007. The event will be held at the Hyatt Regency New Brunswick in New Brunswick, New Jersey from September 24 - 26, 2007.

This three-day conference examines how new approaches to drug delivery are coming to market, how they are changing clinical practice, and what the potential for various technologies is in specific applications. The event will provide an introduction to various drug delivery routes and describe the technologies that are used in each of these routes. Emphasis will be placed on methods developed in recent history rather than the traditional techniques of pharmaceutical compounding.

About Delcath Systems, Inc.
Delcath Systems is the developer of percutaneous perfusion technology for organ- or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug Melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. The Company's intellectual property portfolio currently consists of 18 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website www.delcath.com.